Finerenone (Kerendia) — Evidence Stability Assessment
Coverage and formulary review support • Chronic kidney disease with type 2 diabetes
Claim
Finerenone reduces kidney and cardiovascular risk in adult patients with chronic kidney disease associated with type 2 diabetes.
What Changed
The Wikipedia evidence surface for finerenone has remained stable for 15 months with zero editorial contestation. Five revisions in the observation window were not reverted. The most recent edit (March 26, 2025) was a copy edit in the Medical Uses section. No challenge, reframe, or citation replacement was attempted.
| Date | Edit summary | Reverts | Days to review |
|---|---|---|---|
| 2024-03-03 | update infobox, links | 0 | 469 |
| 2024-10-15 | infobox; original name; brand names; refs; effects | 0 | 243 |
| 2024-10-21 | Added dose and info. I am doctor and was referring this for my lecture tomorrow. | 0 | 237 |
| 2025-03-26 | Copy editing | 0 | 81 |
| 2025-05-29 | Rescued 1 archive link; Move 1 url | 0 | 17 |
What zero reverts means: None of these edits triggered an editorial reversal. The claim surface is not contested on this evidence channel.
Claim Assessment
The evidence surface has been uncontested for 15 months. All revisions in the window were accepted by the editorial community without challenge. This pattern is consistent with institutional knowledge formation preceding formal recognition.
Baseline result (validated): Revert-count baseline scored 1.0 precision / 1.0 recall on holdout for this lane (n=2). Both holdout observations were zero-revert edits close to the review date.
Integrated model (not commercially offered): The 10-factor semantic hardening model scored 0/0 on this lane and remains under refinement. This brief uses only the validated baseline.
Why It Matters Now
The P&T committee review is 30 days away. The evidence surface has been stable since March 2024. No editorial challenge has emerged. For a formulary team, this stability profile means the public knowledge base is not volatile — the claim is harder to dismiss on grounds of active controversy.
The brief does not predict the committee outcome. It measures whether the external evidence surface is contested. On this lane, it is not.
Source Trail
- Wikipedia — Finerenone revision history (en.wikipedia.org/wiki/Finerenone). Observations extracted 2026-04-30. All observations independently verifiable.
-
Holdout validation: Two-event temporal split, zero lookahead. See
backtests/reports/2026-04-30-finerenone-production-hardening-v1.md. - Outcome label: FDA label expansion, 2025-06-15 (independent regulator source). Known outcome; used here for illustration only.
Limits
- n=1 case illustration. This is one historical case, not a generalizable model. The baseline method is validated for this lane only.
- Measures stability, not prediction. The baseline reports whether edits were reverted. It does not forecast FDA, payer, or guideline outcomes.
- Wikipedia is a proxy, not truth. We measure editorial contestation as a signal of institutional knowledge formation, not medical correctness.
- Integrated model excluded. The 10-factor semantic score is reported for research transparency but is not commercially validated.
- Historical outcome known. This brief is reconstructed with hindsight for educational purposes. A live brief is issued before the outcome is known.